CD274 and neoplasm: ICIs, a class of immunomodulatory monoclonal antibodies targeting the PD1/PDL-1 axis, CTLA-4 and other suppressive T cell signaling pathways, have been demonstrated to induce functional recovery of antineoplastic T cell immunity, and this was associated with impressive therapeutic responses in a variety of tumor patients at different stages of disease [116].